Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1649 1675 1678
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18054285 | Compositions Comprising Human Skin Fibroblasts and Amyloid Beta Peptide | Final Rejection | WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY |
| 18546141 | LOW INTENSITY ULTRASOUND COMBINATION CANCER THERAPIES | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17914598 | BETA-ARRESTIN COMPOSITIONS AND ASSOCIATED METHODS | Non-Final OA | Duke University |
| 18255433 | AN LTBR AGONIST IN COMBINATION THERAPY AGAINST CANCER | Non-Final OA | VRIJE UNIVERSITEIT BRUSSEL |
| 17790288 | STRATIFYING RISK OF MALIGNANCY IN INDETERMINATE THYROID NODULES AND IMMUNO-GENOMIC MARKERS FOR EARLY DETECTION OF THYROID CANCER | Final Rejection | The University of Toledo |
| 18211970 | PRODUCTS AND METHODS FOR THE DIAGNOSIS AND DIFFERENTIATION OF HEPARIN-INDUCED THROMBOCYTOPENIA FROM VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA AND NON-HEPARIN-INDUCED THROMBOCYTOPENIA | Non-Final OA | McMaster University |
| 17730484 | EVALUATING METHOD FOR PHARMACOLOGICAL ACTIONS OF IMMUNE CHECKPOINT INHIBITORS, CALCULATING METHOD, EVALUATING APPARATUS, CALCULATING APPARATUS, EVALUATING PROGRAM, CALCULATING PROGRAM, RECORDING MEDIUM, EVALUATING SYSTEM, AND TERMINAL APPARATUS | Final Rejection | AJINOMOTO CO., INC. |
| 18781407 | ANTIBODIES TO UBIQUITIN C-TERMINAL HYDROLASE L1 (UCH-L1) AND GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) AND RELATED METHODS | Non-Final OA | BANYAN BIOMARKERS, INC. |
| 17787968 | Methods for Identifying Modulators of Insect Transient Receptor Potential Channels | Non-Final OA | BASF Corporation |
| 18017841 | PEPTIDE DESIGN AND GALECTIN-3 INHIBITORS | Non-Final OA | City of Hope |
| 18640470 | FELINE ANTIBODY VARIANTS | Non-Final OA | Zoetis Services LLC |
| 17923161 | METHOD FOR DETECTING INFLAMMATION-RELATED PLATELET ACTIVATION | Non-Final OA | UNIVERSITE JEAN MONNET SAINT ETIENNE |
| 18024210 | TEST KIT AND METHOD OF DETERMINING TRYPTOPHAN IN EXTRACTS OF FAECAL SAMPLES | Non-Final OA | IMMUNDIAGNOSTIK AG |
| 18039683 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18379431 | DETECTION OF DEBRIS IN RECIRCULATING PHAGOCYTES | Non-Final OA | ZELOSDX, INC. |
| 18552099 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF ALZHEIMER'S DISEASE | Non-Final OA | UNIVERSIDAD DE CASTILLA LA MANCHA |
| 17633664 | DIAGNOSIS OF CANCER USING DETECTION OF ANTIBODIES DIRECTED AGAINST PD1 AND PD-L1 | Non-Final OA | CELLTREND GMBH |
| 18254699 | IN VITRO METHOD FOR FUNCTIONAL ASSESSMENT OF HAEMATOPOIETIC PROGENITORS | Non-Final OA | INSTITUTO DISTRITAL DE CIENCIA BIOTECNOLOGIA E INNOVACION EN SALUD - IDCBIS |
| 17639428 | DISCERNING BRAIN CANCER TYPE | Non-Final OA | DXCOVER LIMITED |
| 18147716 | METHOD FOR PREPARING BIOCHIP AND BIOCHIP PREPARED THEREFROM | Non-Final OA | NOVASCOPE BIOCHIPS INC. |
| 17634385 | HIGH-SENSITIVITY IMMUNOASSAY FOR THE DETECTION OF FRATAXIN IN BIOFLUIDS | Non-Final OA | VOYAGER THERAPEUTICS, INC. |
| 18054936 | IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases | Final Rejection | AB2 Bio SA |
| 17961412 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND ASSESSING RHEUMATOID ARTHRITIS USING PROTEIN-ARGININE DEIMINASE 1 (PAD1) AUTOANTIGENS | Final Rejection | INOVA DIAGNOSTICS, INC. |
| 17795264 | METHODS AND KIT FOR DETECTION OF ANALYTES | Non-Final OA | BLOODLESS DX, LLC |
| 17761545 | COMPOSITIONS, SYSTEMS, AND METHODS FOR IDENTIFYING A COMPOUND THAT MODULATES ONE OR MORE CHARACTERISTICS ASSOCIATED WITH A RBM20 CONDENSATE AND/OR A RBM20 POLYPEPTIDE | Non-Final OA | Dewpoint Therapeutics, Inc. |
| 17377487 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODAMAGE | Final Rejection | Prince Biotech, LLC |
| 17066961 | FIBROBLAST GROWTH PATTERNS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE | Final Rejection | WEST VIRGINIA UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy